Unequal Access: the Prohibitive Costs of New Drugs in Low- and Middle-income Countries
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Mansfield B, Mohamed F, Larouche M, Raal F
. The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias. J Clin Med. 2024; 13(14).
PMC: 11277596.
DOI: 10.3390/jcm13144160.
View
2.
Seefried L, Smyth M, Keen R, Harvengt P
. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int. 2020; 32(1):7-22.
PMC: 7755619.
DOI: 10.1007/s00198-020-05548-0.
View
3.
Russell M, Galloway J
. Driving down the cost of biologics: lessons from a nationalised health-care system. Lancet. 2024; 404(10464):1723-1724.
DOI: 10.1016/S0140-6736(24)02151-2.
View